Search
Avelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigationalAvelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsAnthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalThis binding of antibody to PA prevents PA-mediated cellular entry of toxic factors. … Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and
Prizloncabtagene autoleucel
go.drugbank.com/drugs/DB18623InvestigationalC-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.
Synonyms: autologous T lymphocytes obtained from peripheral blood lymphocytes by leukapheresis, transduced with a self-inactivating, non-replicating lentiviral vector, encoding a bispecific chimeric antigen receptorUlviprubart
go.drugbank.com/drugs/DB18281InvestigationalSynonyms: immunoglobulin G1-kappa, anti-[Homo sapiens KLRG1(killer cell lectin like receptor G1, MAFA, CLEC15A)], humanized monoclonal antibody, Immunoglobulin G1, anti-(human killer cell lectin-like receptor subfamily G member 1) (human-Mus musculus monoclonal ABC008 γ1-chain), disulfide with human-Mus musculus monoclonal ABC008 κ-chain, dimeTanfanercept
go.drugbank.com/drugs/DB19142InvestigationalTanfanercept is under investigation in clinical trial NCT06400589 (A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease).
Synonyms: 41-211-tumor necrosis factor receptor 1, L-methionyl-(l28>v,s52>m,h55>f,r57>p,h58>g,k121>n) tumor necrosis factor (tnf) binding protein variant 1 (tbp-1) with c-terminal extension by further 10 residues of the pro-protein, human, unglycosylatedAnti-CD19 CAR-T cells
go.drugbank.com/drugs/DB21913InvestigationalCD19 CAR-T is under investigation in clinical trial NCT05618041 (The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients with Hematological Malignancies).
Synonyms: CD19 Chimeric Antigen Receptor (CAR) T cellsRopeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigational[A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials. … [A242000, A242005] [Interferon alfa-2b] has been used for decades to treat PV but requires frequent dosing and is not tolerated by all patients.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2A6 InhibitorsSynonyms: PEG-P-IFN-alfa-2b, PEG-P-IFN-alpha-2bBenzquinamide
go.drugbank.com/drugs/DB00767ApprovedWithdrawnThe mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic acetycholine receptors and histamine H1 receptors.
Categories: P-glycoprotein inhibitorsDurvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigational[A192789] Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture,[L12621] durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors